These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 28978166)

  • 1. Metabolomic biomarkers of pancreatic cancer: a meta-analysis study.
    Mehta KY; Wu HJ; Menon SS; Fallah Y; Zhong X; Rizk N; Unger K; Mapstone M; Fiandaca MS; Federoff HJ; Cheema AK
    Oncotarget; 2017 Sep; 8(40):68899-68915. PubMed ID: 28978166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolomics identified new biomarkers for the precise diagnosis of pancreatic cancer and associated tissue metastasis.
    Luo X; Liu J; Wang H; Lu H
    Pharmacol Res; 2020 Jun; 156():104805. PubMed ID: 32278036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum metabolomics differentiating pancreatic cancer from new-onset diabetes.
    He X; Zhong J; Wang S; Zhou Y; Wang L; Zhang Y; Yuan Y
    Oncotarget; 2017 Apr; 8(17):29116-29124. PubMed ID: 28418859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue metabolomics identified new biomarkers for the diagnosis and prognosis prediction of pancreatic cancer.
    Liu C; Qin H; Liu H; Wei T; Wu Z; Shang M; Liu H; Wang A; Liu J; Shang D; Yin P
    Front Oncol; 2022; 12():991051. PubMed ID: 36119530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serological Phenotyping Analysis Uncovers a Unique Metabolomic Pattern Associated With Early Onset of Type 2 Diabetes Mellitus.
    Zhu L; Huang Q; Li X; Jin B; Ding Y; Chou CJ; Su KJ; Zhang Y; Chen X; Hwa KY; Thyparambil S; Liao W; Han Z; Mortensen R; Jin Y; Li Z; Schilling J; Li Z; Sylvester KG; Sun X; Ling XB
    Front Mol Biosci; 2022; 9():841209. PubMed ID: 35463946
    [No Abstract]   [Full Text] [Related]  

  • 6. Identification of highly sensitive biomarkers that can aid the early detection of pancreatic cancer using GC/MS/MS-based targeted metabolomics.
    Hirata Y; Kobayashi T; Nishiumi S; Yamanaka K; Nakagawa T; Fujigaki S; Iemoto T; Kobayashi M; Okusaka T; Nakamori S; Shimahara M; Ueno T; Tsuchida A; Sata N; Ioka T; Yasunami Y; Kosuge T; Kaneda T; Kato T; Yagihara K; Fujita S; Yamada T; Honda K; Azuma T; Yoshida M
    Clin Chim Acta; 2017 May; 468():98-104. PubMed ID: 28215548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel mixed integer programming for multi-biomarker panel identification by distinguishing malignant from benign colorectal tumors.
    Zou M; Zhang PJ; Wen XY; Chen L; Tian YP; Wang Y
    Methods; 2015 Jul; 83():3-17. PubMed ID: 25980368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Commonality and differences of methylation signatures in the plasma of patients with pancreatic cancer and colorectal cancer.
    Melson J; Li Y; Cassinotti E; Melnikov A; Boni L; Ai J; Greenspan M; Mobarhan S; Levenson V; Deng Y
    Int J Cancer; 2014 Jun; 134(11):2656-62. PubMed ID: 24288256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolomics based predictive classifier for early detection of pancreatic ductal adenocarcinoma.
    Unger K; Mehta KY; Kaur P; Wang Y; Menon SS; Jain SK; Moonjelly RA; Suman S; Datta K; Singh R; Fogel P; Cheema AK
    Oncotarget; 2018 May; 9(33):23078-23090. PubMed ID: 29796173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolomic profile in pancreatic cancer patients: a consensus-based approach to identify highly discriminating metabolites.
    Di Gangi IM; Mazza T; Fontana A; Copetti M; Fusilli C; Ippolito A; Mattivi F; Latiano A; Andriulli A; Vrhovsek U; Pazienza V
    Oncotarget; 2016 Feb; 7(5):5815-29. PubMed ID: 26735340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NMR-based metabolomic techniques identify potential urinary biomarkers for early colorectal cancer detection.
    Wang Z; Lin Y; Liang J; Huang Y; Ma C; Liu X; Yang J
    Oncotarget; 2017 Dec; 8(62):105819-105831. PubMed ID: 29285295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma metabolite biomarkers for the detection of pancreatic cancer.
    Xie G; Lu L; Qiu Y; Ni Q; Zhang W; Gao YT; Risch HA; Yu H; Jia W
    J Proteome Res; 2015 Feb; 14(2):1195-202. PubMed ID: 25429707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individualized metabolic profiling stratifies pancreatic and biliary tract cancer: a useful tool for innovative screening programs and predictive strategies in healthcare.
    Lee JH; Yu SE; Kim KH; Yu MH; Jeong IH; Cho JY; Park SJ; Lee WJ; Han SS; Kim TH; Hong EK; Woo SM; Yoo BC
    EPMA J; 2018 Sep; 9(3):287-297. PubMed ID: 30174764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid differentiating colorectal cancer and colorectal polyp using dried blood spot mass spectrometry metabolomic approach.
    Jing Y; Wu X; Gao P; Fang Z; Wu J; Wang Q; Li C; Zhu Z; Cao Y
    IUBMB Life; 2017 May; 69(5):347-354. PubMed ID: 28322027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An integrated proteomics and metabolomics approach for defining oncofetal biomarkers in the colorectal cancer.
    Ma Y; Zhang P; Wang F; Liu W; Yang J; Qin H
    Ann Surg; 2012 Apr; 255(4):720-30. PubMed ID: 22395091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Detection of Pancreatic Cancer in Type 2 Diabetes Mellitus Patients Based on
    Michálková L; Horník Š; Sýkora J; Habartová L; Setnička V; Bunganič B
    J Proteome Res; 2021 Mar; 20(3):1744-1753. PubMed ID: 33617266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A validated metabolomic signature for colorectal cancer: exploration of the clinical value of metabolomics.
    Farshidfar F; Weljie AM; Kopciuk KA; Hilsden R; McGregor SE; Buie WD; MacLean A; Vogel HJ; Bathe OF
    Br J Cancer; 2016 Sep; 115(7):848-57. PubMed ID: 27560555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of human complement factor B as a novel biomarker candidate for pancreatic ductal adenocarcinoma.
    Lee MJ; Na K; Jeong SK; Lim JS; Kim SA; Lee MJ; Song SY; Kim H; Hancock WS; Paik YK
    J Proteome Res; 2014 Nov; 13(11):4878-88. PubMed ID: 25057901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolomic biomarkers of impaired glucose tolerance and type 2 diabetes mellitus with a potential for risk stratification in women with polycystic ovary syndrome.
    Galazis N; Iacovou C; Haoula Z; Atiomo W
    Eur J Obstet Gynecol Reprod Biol; 2012 Feb; 160(2):121-30. PubMed ID: 22136882
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.